Across TCGA pan-cancer cohorts, CDCA2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CDCA2 data layer compared with 28 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CDCA2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDCA2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
KIRC, KICH, and UCEC are the cancer types where CDCA2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.